Stifel Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

Stifel Financial’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$956K	Buy	43,714 +2,000	+5%	+$41.6K	﹤0.01%	2588
2026 Q1	$974K	Sell	41,714 -34,200	-45%	-$743K	﹤0.01%	2471
2025 Q4	$1.59M	Sell	75,914 -22,427	-23%	-$391K	﹤0.01%	2099
2025 Q3	$1.51M	Buy	98,341 +9,239	+10%	+$121K	﹤0.01%	2110
2025 Q2	$834K	Buy	89,102 +14,750	+20%	+$162K	﹤0.01%	2455
2025 Q1	$913K	Buy	74,352 +36,877	+98%	+$520K	﹤0.01%	2292
2024 Q4	$495K	Buy	37,475 +20,499	+121%	+$351K	﹤0.01%	2679
2024 Q3	$327K	Buy	+16,976	New	+$351K	﹤0.01%	2913

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Stifel Financial's SNDX Position: Q2 2026 in Review

Stifel Financial increased its Syndax Pharmaceuticals (SNDX) stake by 4.8% in Q2 2026, buying an estimated $41.6K and bringing the position to 43,714 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #2588.

Stifel Financial first reported a position in SNDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.59M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Stifel Financial held 43,714 shares of Syndax Pharmaceuticals worth $956K as of Q2 2026.
Stifel Financial bought 2,000 Syndax Pharmaceuticals shares in Q2 2026, an estimated $41.6K.
Syndax Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2588 holding.
Stifel Financial first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Stifel Financial's Syndax Pharmaceuticals position peaked at $1.59M in Q4 2025.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.